Retatrutide Expected Results: Phase 2 Data and Projections
Retatrutide is a next-generation triple hormone receptor agonist that activates GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 clinical trial data, published in the New England Journal of Medicine in 2023, showed unprecedented weight loss results of up to 24.2% of body weight at 48 weeks. If Phase 3 trials confirm these findings, retatrutide could become the most effective weight loss medication ever approved.
Medical Disclaimer: This article is for informational purposes only. Retatrutide is an investigational drug not yet approved by the FDA. Phase 2 data may not predict Phase 3 outcomes. Do not use investigational drugs outside of clinical trials.
Phase 2 Trial Results by Dose
| Retatrutide Dose | Avg. % Body Weight Lost (48 wks) | Avg. lbs (230 lb start) | % Achieving 15%+ Loss |
|---|---|---|---|
| 1 mg | -8.7% | ~20 lbs | ~25% |
| 4 mg | -17.1% | ~39 lbs | ~63% |
| 8 mg | -22.8% | ~52 lbs | ~83% |
| 12 mg | -24.2% | ~56 lbs | ~93% |
| Placebo | -2.1% | ~5 lbs | ~3% |
Head-to-Head Comparison: The GLP-1 Landscape
| Medication | Mechanism | Max Avg. Weight Loss | Trial Duration | Status |
|---|---|---|---|---|
| Semaglutide 2.4 mg | GLP-1 only | -14.9% | 68 weeks | FDA approved |
| Tirzepatide 15 mg | GIP + GLP-1 | -20.9% | 72 weeks | FDA approved |
| Retatrutide 12 mg | GIP + GLP-1 + Glucagon | -24.2% | 48 weeks | Phase 3 trials |
The comparison is striking: retatrutide achieved 24.2% weight loss in just 48 weeks, while tirzepatide needed 72 weeks to reach 20.9% and semaglutide needed 68 weeks for 14.9%. Notably, the weight loss curves in retatrutide's Phase 2 trial had not yet plateaued at 48 weeks, suggesting even greater results might be seen in longer trials.
How Retatrutide Works Differently
Retatrutide's triple receptor agonism provides three complementary mechanisms:
- GLP-1 receptor: Reduces appetite, slows gastric emptying, and improves insulin secretion, similar to semaglutide.
- GIP receptor: Enhances insulin sensitivity and may improve fat metabolism, similar to tirzepatide's dual action.
- Glucagon receptor: The key differentiator. Glucagon activation increases energy expenditure (metabolic rate), promotes fat oxidation, and may reduce liver fat more effectively than GLP-1 or GIP alone.
Expected Timeline to Approval
| Milestone | Estimated Timeline |
|---|---|
| Phase 3 trials enrollment | 2024-2025 (underway) |
| Phase 3 results | Late 2026 - 2027 |
| FDA submission | 2027 |
| Potential FDA approval | Late 2027 - 2028 |
Side Effects in Phase 2
The most common side effects in the Phase 2 trial were similar to other GLP-1 medications:
- Nausea: 16-25% depending on dose
- Diarrhea: 15-22%
- Vomiting: 6-13%
- Constipation: 6-12%
- Decreased appetite: Universal (this is the intended therapeutic effect)
The discontinuation rate due to adverse events was approximately 6% across dose groups, comparable to existing GLP-1 medications.
What This Means for Patients Today
Retatrutide represents the future of weight loss pharmacotherapy, but it is not yet available outside of clinical trials. For patients seeking treatment today, semaglutide and tirzepatide remain the gold-standard options with proven, FDA-approved track records. At Trimi, we offer both semaglutide and tirzepatide with personalized clinical support, and we will incorporate new treatment options like retatrutide as they become available.
Frequently Asked Questions
How much weight loss does retatrutide produce?
Up to 24.2% of body weight at 48 weeks in Phase 2 trials at the 12 mg dose. This is the highest weight loss ever achieved with a pharmaceutical intervention in clinical trials.
When will retatrutide be available?
It is currently in Phase 3 trials. If successful, earliest FDA approval is estimated for late 2027 or 2028. This timeline is subject to change based on trial outcomes and regulatory review.
How does retatrutide compare to tirzepatide and semaglutide?
Phase 2 data shows retatrutide produces greater weight loss (24.2%) than tirzepatide (20.9%) and semaglutide (14.9%), in a shorter timeframe. Phase 3 data is needed to confirm these results in larger, longer trials.
For treatment with today's best available GLP-1 medications, explore Trimi's programs.
More on GLP-1 Results & Outcomes
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).